OTO 825
Alternative Names: OTO-825Latest Information Update: 28 Mar 2024
At a glance
- Originator Applied Genetic Technologies Corporation; Otonomy
- Developer Beacon Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Membrane transport protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Hearing loss
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Hearing loss in USA (Intratympanic, Injection)
- 04 Aug 2021 Otonomy and Applied Genetic Technologies Corporation plans to file IND with the US FDA for Hearing loss in the first half of 2023
- 21 May 2021 Pharmacodynamics data from preclinical studies in Hearing loss released by Otonomy